Skip to main content
. 2023 Mar 16;24(1):26. doi: 10.1186/s10194-023-01560-x

Fig. 4.

Fig. 4

Galcanezumab effects on migraine days per month in (A) all 46 patients, (B) 24 responders only, and (C) 19 non-responders. Differences in percentages of migraine days per month at baseline (before treatment) and in each of the 3 treatment months are shown in box-and-whisker plots (median [IQR]) combined with scatterplots of individual values. Note that the percentage of migraine days per month decreased significantly, although to a different extent, in all 3 groups